Semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD. In addition to improvements in walking ability and function, people taking semaglutide also saw significant improvements in both symptoms and quality of life compared with those taking a placebo.